...in addition to blocking SERT. Steve Schow, industry consultant and former VP of R&D at Telik Inc.... ...inhibitor, we are more or less done exploiting this transporter in drug design." In 2014, Telik...
...ready for the clinic." According to Steve Schow, consultant and former VP of R&D at Telik Inc.... ...really been a major issue for cationic antimicrobials," he said. MabVax Therapeutics Inc. reverse-merged with Telik...
...anticoagulant effect. The path forward Steve Schow, industry consultant and former VP of R&D at Telik Inc.... ...become the first drug based on a dendritic scaffold. MabVax Therapeutics Inc. reverse merged with Telik...
...MabVax reverse-merged with Telik in a stock deal. Following the close, MabVax shareholders own 82% of... ...through the sale of 1.2 million MabVax shares at $2.59, which were converted to 2.23 Telik... ...stock for $1.5 million (see BioCentury, May 19). MabVax Therapeutics Inc. , San Diego, Calif. Telik Inc....
...are in Phase II testing: Telintra ezatiostat hydrochloride, an IV peptidomimetic glutathione S-transferase inhibitor from Telik Inc.... ...Companies and Institutions Mentioned Myelo Therapeutics GmbH , Berlin, Germany PledPharma AB , Stockholm, Sweden Telik Inc....
...in a stock deal to create a publicly traded company named MabVax Therapeutics Holdings Inc. Telik... ...president, CEO and chairman of the combined company; and Michael Wick, president and CEO of Telik... ...Telik, which could not be reached for details. MabVax Therapeutics Inc. , San Diego, Calif. Telik Inc....
...projects. Steven Schow, an adviser on the program and VP of R&D at cancer company Telik Inc.... ...Alto, Calif. Stanford University , Stanford, Calif. Stanford University School of Medicine , Stanford, Calif. Telik Inc....
...in addition to blocking SERT. Steve Schow, industry consultant and former VP of R&D at Telik Inc.... ...inhibitor, we are more or less done exploiting this transporter in drug design." In 2014, Telik...
...ready for the clinic." According to Steve Schow, consultant and former VP of R&D at Telik Inc.... ...really been a major issue for cationic antimicrobials," he said. MabVax Therapeutics Inc. reverse-merged with Telik...
...anticoagulant effect. The path forward Steve Schow, industry consultant and former VP of R&D at Telik Inc.... ...become the first drug based on a dendritic scaffold. MabVax Therapeutics Inc. reverse merged with Telik...
...MabVax reverse-merged with Telik in a stock deal. Following the close, MabVax shareholders own 82% of... ...through the sale of 1.2 million MabVax shares at $2.59, which were converted to 2.23 Telik... ...stock for $1.5 million (see BioCentury, May 19). MabVax Therapeutics Inc. , San Diego, Calif. Telik Inc....
...are in Phase II testing: Telintra ezatiostat hydrochloride, an IV peptidomimetic glutathione S-transferase inhibitor from Telik Inc.... ...Companies and Institutions Mentioned Myelo Therapeutics GmbH , Berlin, Germany PledPharma AB , Stockholm, Sweden Telik Inc....
...in a stock deal to create a publicly traded company named MabVax Therapeutics Holdings Inc. Telik... ...president, CEO and chairman of the combined company; and Michael Wick, president and CEO of Telik... ...Telik, which could not be reached for details. MabVax Therapeutics Inc. , San Diego, Calif. Telik Inc....
...projects. Steven Schow, an adviser on the program and VP of R&D at cancer company Telik Inc.... ...Alto, Calif. Stanford University , Stanford, Calif. Stanford University School of Medicine , Stanford, Calif. Telik Inc....
